[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":82},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100589958","observational-study-of-platelet-dysfunction-assessed-by-thromboelastography-in-cardiovascular-surgery-displateg-100589958",false,"NCT06961175","Observational Study of Platelet Dysfunction Assessed by Thromboelastography in Cardiovascular Surgery (DISPLATEG)","Observational Study of Preoperative or Extracorporeal Circulation-induced Platelet Dysfunction Assessed by Thromboelastography in Non-antiplatelet-treated Patients Undergoing Cardiovascular Surgery (DISPLATEG Study)","DISPLATEG","Inclusion Criteria:\n\n* Over 18 years of age.\n* Patients undergoing elective surgery under CPB.\n* Patients must be duly informed and have signed the informed consent form.\n* ASA status I-IV.\n* Sufficient intellectual capacity to understand the procedure.\n* Normal preoperative coagulation study and platelet count.\n\nExclusion Criteria:\n\n* Failure to meet the criteria listed above.\n* Preoperative administration of antiplatelet agents with an inadequate washout period (5 days for clopidogrel and ticagrelor and 7 days for plasugrel).\n* Preoperative administration of anticoagulants with an inadequate washout period.\n* Thrombopenia \\\u003C100,000 platelets or anemia \\\u003C11 g\u002FdL",true,"ALL","18 Years",{"count":21,"type":22},180,"ESTIMATED","OBSERVATIONAL","Perioperative bleeding requiring blood transfusion is common during cardiovascular surgery, especially in procedures requiring cardiopulmonary bypass. Adenosine diphosphate (ADP) plays a fundamental role in platelet function. Several studies have shown that some patients not receiving antiplatelet therapy undergoing cardiovascular surgery have decreased platelet ADP receptor activity; the prevalence of this condition can be as high as 36%.\n\nFurthermore, extracorporeal circulation itself has been shown to cause a reduction in platelet function. Platelet dysfunction due to reduced platelet receptor activity after cardiac surgery is potentially a common cause of bleeding, perioperative blood transfusion, and surgical reexploration in patients not receiving antiplatelet agents. However, these studies are conducted with few patients and present some contradictory results, so the evidence is still scarce.\n\nThe study hypothesis is that preoperative platelet dysfunction for ADP measured by TEG® Platelet Mapping™ is associated with a higher incidence of moderate-severe bleeding after CPB in patients undergoing cardiovascular surgery.",[26,27,28],"Blood Platelet Disorders","Cardiac Surgery","Postoperative Bleeding","RECRUITING","2025-08-04",{"date":32,"type":33},"2025-08-08","ACTUAL",{"date":35,"type":33},"2025-05-01",{"date":37,"type":22},"2026-12",{"name":39,"class":40},"Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":18,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},"100340330","cardiovascular-prevention-strategies-in-elderly-patients-with-cancer-cartier-clinical-trial-100340330","NCT03711110","Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial)","Cardiotoxicity in the Elderly. Comparative Clinical Trial Between Primary Versus Secondary Cardiovascular Prevention Strategies","CARTIER","Inclusion Criteria:\n\n* \\> 65 years old\n* Expected survival \\>1 year\n* Colon cancer, breast cancer, lymphoma, chronic lymphoma leukemia, chronic myeloid leukemia, myeloma\n* Signature on the informed consent\n\nExclusion Criteria:\n\n* Patients included in clinical trials will be excluded if they interfere with the CARTIER follow-up protocol. If they do not interfere they can be included\n* Patients who had received previous potentially cardiotoxic anticancer treatment","65 Years",{"count":52,"type":22},514,"INTERVENTIONAL",[55],"NA","The CARTIER study is a randomized, multicenter, open-label clinical trial comparing, in elderly patients with cancer under anti-tumoral treatment, two different cardiotoxicity prevention strategies: primary (intensive cardiovascular monitoring focused on prevention and early diagnosis and treatment of cardiotoxicity based in cardio-onco-hematology teams involved in cancer patient care) vs. secondary (current clinical practice where intensive cardiovascular monitoring is not routinely performed and cardiotoxicity patient care is based on the onco-hematologist criteria).\n\nThe primary endpoint is to determine whether this primary prevention englobing cardiovascular monitoring plus intensive multidisciplinary management is superior to the current clinical practice in reducing all cause mortality.\n\nOther secondary objectives of the study are to analyze the impact of this intensive cardiovascular monitoring strategy on the incidence of cardiovascular mortality, oncological mortality, hospitalization and\u002For urgent care due to cardiovascular complications, hospitalization and\u002For urgent oncological care due to cancer complications, tumor progression and cost-effectiveness analysis.\n\nA total of 514 patients ≥ 65 years old diagnosed with any of the following onco-hematological cancers, colon, breast, lymphoma, chronic lymphoma leukemia, chronic myeloid leukemia or myeloma, undergoing standardized anti-tumoral treatment, will be recruited.\n\nThe incidence of primary and secondary outcomes will be measured at 2 and 5 years",[58,59,60,61],"Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma)","Elderly","Antineoplastic Agents","Cardiotoxicity",[61,59,63,64,65,66,67,68,69,70,71,72],"Antineoplastic agents","Cardiovascular monitoring","Cardioprotection","Cardio-oncology","Chemically-Induced Disorders","Radiation Injuries","Drug-Related Side Effects and Adverse Reactions.","Primary prevention","Secondary prevention.","Mortality","2025-03-18",{"date":75,"type":33},"2025-03-21",{"date":77,"type":33},"2019-08-02",{"date":79,"type":22},"2025-11-30",{"name":39,"class":40},14,""]